Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quintiles to Acquire Novella Clinical

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
Acquisition bolsters Quintiles’ small biopharma, oncology and medical device capabilities.

To stay ahead of the diverse and evolving needs of its global customer base, Quintiles has announced that it has signed an agreement to acquire Novella Clinical (Novella), a full-service clinical research organization (CRO) focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors.

“The expertise and insight the Novella team brings will be a strong addition to our existing capabilities and help further differentiate Quintiles in an increasingly competitive marketplace,” said Paula Brown Stafford, President, Clinical Development at Quintiles.

Stafford continued, “Novella’s understanding of emerging companies, as well as our shared commitment to quality, customer service, and above all, the patients we ultimately serve, makes this acquisition a good fit for both organizations. We look forward to working collaboratively with Novella to leverage the synergies that exist between our companies to help drive business growth while continuing to meet the needs of our customers.”

Novella’s infrastructure and approach to clinical research were created with the operational needs of its unique customer base in mind, and constructed to best support these specific customer groups.

By joining Quintiles, Novella will be able to continue this specialized focus while at the same time leveraging Quintiles’ scale and resources to provide new global capabilities to its existing and future customers.

“We are extremely excited about the opportunity to join Quintiles - the global leader in our industry,” said Richard Staub, President and CEO of Novella. “Since our founding fifteen years ago, Novella has been committed to serving emerging companies by offering personal attention and flexibility in addition to our extensive therapeutic experience. By joining Quintiles, we will be able to extend the geographic reach of our services exponentially while remaining committed to the values and business approach that makes us a great partner to our customers.”

Novella is headquartered in Research Triangle Park, N.C., and has more than 800 professionals located throughout North America and Europe.

Upon completion of this transaction, Novella will operate as a unit within Quintiles and be known as “Novella Clinical, a Quintiles company.” The transaction, which is subject to standard and customary closing conditions, is expected to close later this quarter.

Financial terms of the transaction are not being disclosed. The acquisition is not expected to have a material impact on Quintiles’ 2013 earnings per share.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quintiles Launches Suite of Services to IADP
New offering incorporates clinical, commercial and regulatory insight to improve the probability of an asset’s commercial success.
Friday, December 18, 2015
Quest, Quintiles Launch Joint Venture
The companies have announced that they have launched their previously announced joint venture, a clinical trials lab business dubbed Q2 Solutions.
Friday, July 03, 2015
Quintiles Officially Opens Greater China Regional Headquarters in Shanghai
New HQ reflects importance & interconnectivity of Greater China’s biopharma industry.
Friday, June 05, 2015
Quintiles Launches New Solution for Emerging Asia-Pacific Companies
Emerging Companies give region strong base to transform global healthcare.
Thursday, May 28, 2015
Quintiles Establishes Bioanalytical Laboratory in Europe
Provides additional depth and scale to existing bioanalytical laboratory capabilities, services and expertise.
Thursday, May 07, 2015
Quintiles and Quest Diagnostics to Form Joint Venture
Combines the complementary strengths and scale of leading biopharmaceutical services and diagnostic information services providers.
Thursday, April 02, 2015
Quintiles Emerging Biopharma Solution Launched
Quintiles launches new customer solution to meet the unique needs of emerging biopharmaceutical companies.
Tuesday, September 16, 2014
Quintiles Recieves Phase II/III Clinical Research Industry Accolade
Biopharma recognizes Quintiles as the leader in customer loyalty among large Clinical Research Organizations (CROs) in quality benchmarking report.
Wednesday, May 22, 2013
Merck Serono and Quintiles Announce Innovative Clinical Development Partnership
Agreement creates unique strategic collaboration for development and clinical trial execution.
Friday, May 17, 2013
Quintiles Acquires Expression Analysis
Acquisition of premier provider of genomics services to advance personalized medicine.
Tuesday, August 14, 2012
Quintiles Announces Clinical Research Partnership with the University Malaya Medical Centre
Quintiles Prime Site program expands into Asia to accelerate clinical development.
Tuesday, July 06, 2010
Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development
Quintiles and SCPMG to work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site.
Friday, May 21, 2010
Quintiles Takes Action to Speed Development of Cancer Therapies
Company has adopted “common contract language” and will be using the standardized contract clauses developed by the CEO Roundtable on Cancer.
Thursday, January 15, 2009
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!